Latest news with #ARSPharmaceuticals
Yahoo
27-05-2025
- Business
- Yahoo
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer, will participate in presentations at the William Blair 45th Annual Growth Stock Conference and 2025 Jefferies Global Healthcare Conference in June. Details outlined below. William Blair 45th Annual Growth Stock ConferencePresentation: Tuesday, June 3, 2025Time: 11:20 a.m. CTLocation: ChicagoA live webcast of the presentation will be available here. 2025 Jefferies Global Healthcare ConferencePresentation: Wednesday, June 4, 2025Time: 5:30 p.m. ETLocation: New York CityA live webcast of the presentation will be available here. ARS Pharma company management will also participate in one-on-one meetings with investors at the Scotiabank Third Annual Healthcare Canadian Investor Day, Tuesday, June 17, 2025, in Toronto. To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the 'Investors & Media' section of the Company's website. A replay of each of the webcasts will be available for 30 days following the event. About ARS Pharmaceuticals, Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing (trade name EUR in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit Investor Contact:Justin Chakma, ARS Pharmajustinc@ Media Contact:Christy Curran, Sam Brown in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.52, delivering a surprise of 1,400%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. ARS Pharmaceuticals, Inc. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $7.97 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.03%. This compares to zero revenues a year ago. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. ARS Pharmaceuticals, Inc. Shares have added about 26.5% since the beginning of the year versus the S&P 500's gain of 0.1%. While ARS Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for ARS Pharmaceuticals, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $15.45 million in revenues for the coming quarter and -$1.28 on $89.27 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, ProPhase Labs, Inc. (PRPH), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of -157.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ProPhase Labs, Inc.'s revenues are expected to be $2.45 million, down 32.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ARS Pharmaceuticals, Inc. (SPRY) : Free Stock Analysis Report ProPhase Labs, Inc. (PRPH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Magazine
08-05-2025
- Health
- Time Magazine
Richard Lowenthal
For decades, people suffering life-threatening allergic reactions had to quickly and correctly give themselves an injection using an EpiPen. That changed in August, when the U.S. Food and Drug Administration approved neffy, a nasal spray that treats severe allergic reactions, including anaphylaxis—making it the first needle-free option for those over age 4. 'People are terrified of the injectors, and that leads to poor treatment because they won't inject themselves at the right time, if at all,' says Richard Lowenthal, a biochemist who's the CEO and president of ARS Pharmaceuticals, the company that makes neffy. The nasal spray is small enough to carry in a shirt pocket. 'It's not threatening, and it doesn't cause significant pain,' Lowenthal says. 'You're spraying medicine in your nose, but it's not irritating, and it's very quick to do—you just put it in and push the plunger, and it's done.' In January, ARS Pharmaceuticals launched its neffyinSchools program, which provides free single-use doses of the drug to eligible K-12 schools in the U.S. Lowenthal was motivated by the fact that up to 25% of kids have their first allergic reaction at school. 'Nurses are thrilled about neffy,' he says, 'and we're very happy that we can step in and give an option.'
Yahoo
05-05-2025
- Health
- Yahoo
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its first quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be available for 30 days following the event. About ARS Pharmaceuticals, Inc. ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing ® (trade name EUR® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit Investor Contact:Justin Chakma, ARS Pharmajustinc@ Media Contact:Christy Curran, Sam Brown in to access your portfolio
Yahoo
05-04-2025
- Business
- Yahoo
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money
We recently published a list of . In this article, we are going to take a look at where ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) stands against other unstoppable stocks that could double your money. Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors. However, high excess returns (alpha) are challenging to generate, let alone doubling money. For example, if someone took a bet on the overall economy and bought the broader market index, it would have taken around five to seven years for them to double the investments, as these indices usually take that much time, depending on the economic cycle and market trends. Such gains are never easy to replicate, but certain companies and sectors are better positioned for high growth due to strong fundamentals, innovation, or macroeconomic trends. Investors who can identify these stocks through research and understanding market cycles can generate extra returns. Moreover, specific stocks' valuation and growth trajectory over the next few years must be precisely analysed to make good returns. Over the last five years, the stock market has been highly dynamic, reflecting broader economic shifts, interest rate cycles, and technological advancements. While 2023 and 2024 were volatile because of concerns over inflation, the Federal Reserve policy, and geopolitical tensions, 2025 has been equally volatile, with the S&P 500 down 3% and the Nasdaq down around 8% (as of March 27). This volatility makes higher returns riskier. Nevertheless, market analysts are still optimistic about gains in 2025. In an interview with CNBC on April 1, Chris Hyzy, Merrill and BofA Private Bank CIO, said he would use recent market weakness to increase positions and favour broad market exposure through equal-weighted S&P positions. He identifies financials and consumer discretionary stocks as particularly oversold and attractive. He also believes that certain areas, like software and cybersecurity, could lead the technology sector in share market gains in the coming months. Chris also suggested that while uncertainty may persist into the summer, markets will likely begin pricing in anticipated improvements in economic conditions and corporate earnings later in the year. According to his assessment, the job market remains stable and strong, which would mean a sharp economic downturn is unlikely. He expects the market to experience a 'sawtooth bottom' rather than a sharp V-shaped recovery, suggesting that long-term opportunities remain despite persisting volatility. Fundstrat's head of research, Tom Lee, stated to CNBC on March 31 that market conditions indicate oversold status and potential bottom formation regardless of ongoing downward trends. Investors maintain their focus on government policies and tariff situations, and their economic impact. According to his estimates, the April 2 tariff updates should also clarify the future of policies and could potentially reduce selling pressure in the market. He also believes that as and when the Federal Reserve communicates further on interest rates, inflation, and other policies, it should provide more direction to investors. In essence, opportunities could emerge in the near term, and investors should look for better entry points to create positions to generate more substantial returns. But stock selection also remains key. According to Goldman Sachs Asset Management's March 24 report, Embracing a Broader Equity Landscape, while the technology sector remains a key driver of growth in 2025, the dominance of a few large U.S. tech companies appears to be waning. The authors highlighted that capital is beginning to diversify beyond the Magnificent 7, and many of today's market leaders may not sustain their positions at the top. This evolving market dynamic presents new opportunities for active investors, particularly in smaller-cap equities, high-quality businesses outside the U.S., and differentiated long-term investment themes. As leadership broadens, they believe this shift could mark the beginning of a more favorable environment for stock selection across the global equity landscape. In recent months, many analysts and fund managers have favored diversifying towards small- and mid-cap stocks; thus, this space should remain on investors' radars. At the same time, investors should be aware of the risks involved in high-performing equities. To identify the unstoppable stocks that could double investors' money, we used online screeners to compile a list of U.S.-listed companies with a market capitalization exceeding $2 billion and with a greater than 20% return in the last one year. We then applied an additional criterion, considering only those stocks with an expected upside of around 100% or more. From the refined list, we took the top 10 stocks with the highest upside potential and ranked them in ascending order of respective upsides. Additionally, we provided insights into hedge fund sentiment surrounding these stocks, using data from Insider Monkey's Q4 2024 are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A laboratory technician processing a batch of medication in an industrial setting. 1-Year Return: 27% ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a biopharmaceutical company focused on developing neffy, a needle-free epinephrine nasal spray designed to treat severe allergic reactions, including anaphylaxis which is known as a fatal condition. Neffy is intended to offer a quick, effective, and user-friendly alternative to traditional epinephrine auto-injectors. Currently, except for neffy, epinephrine is the only approved in injectable form for the emergency treatment of Type I allergic reactions. With more launches planned, neffy is positioned to be the first needle-free, easy-to-use epinephrine rescue option, giving patients a new, more convenient choice. The company sees a significant market opportunity, with management estimating a potential multi-billion-dollar market ($3 billion prescription segment and up to a $7 billion expansion segment), driven by healthcare providers and patient preference. On March 7, William Blair analyst Lachlan Hanbury Brown reaffirmed a Buy rating on ARS Pharmaceuticals (NASDAQ:SPRY), noting positive early indicators following neffy's launch. The company slightly exceeded revenue expectations, reflecting solid initial demand. The analyst also noted progress with healthcare providers, as many have already prescribed neffy and shared encouraging feedback through the neffy experience program. The company also secured favourable insurance coverage with key players like Express Scripts and Cigna, which is expected to accelerate market access faster than planned. Overall, SPRY ranks 5th on our list of unstoppable stocks that could double your money. While we acknowledge the potential of SPRY to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than SPRY but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
